Table 3.

Sensitivity and specificity of screening HIV tests compared to a strategy including pooled HIV NAAT, among PHSKC STD Clinic participants only.

	# tests	Sensitivity (95% CI) compared to all cases	Sensitivity (95% CI) compared to EIA+ cases	Specificity (95% CI)
OraQuick (oral fluid)	2180	51/68 = 75.0% (63.0–84.7)	51/60 = 85.0% (73.4–92.9)	2109/2112 = 99.86% (99.59–99.97)
OraQuick (fingerstick)	2175	53/68 = 77.9% (66.2–87.1)	53/60 = 88.3% (77.4–95.2)	2107/2107 = 100% (99.82–100)
Uni-Gold	1614	45/53 = 84.9% (72.4–93.3)	45/47 = 95.7% (85.5–99.5)	1561/1561 = 100% (99.76–100)
INSTI	559	11/15 = 73.3% (44.9–92.2)	11/13 = 84.6% (54.6–98.1)	543/544 = 99.82% (98.98–100)
Determine Combo	1523	34/40 = 84.6% (70.2–94.3)	33/36* = 91.7% (77.5–98.2)	1468/1483 = 98.99% (98.34–99.43)
GS HIV-1/HIV-2 Plus O antibody (EIA)	2161	58/66 = 87.9% (77.5–94.6)		2091/2095 = 99.81% (99.51–99.95)

^*This numerator and denominator do not include the participant who tested EIA-negative but p24 Ag-positive on Determine Combo.

Note: estimates cannot be directly compared, as not all POC tests were used on all participants.